首页> 美国卫生研究院文献>PLoS Clinical Trials >Urinary Aminopeptidase Activities as Early and Predictive Biomarkers of Renal Dysfunction in Cisplatin-Treated Rats
【2h】

Urinary Aminopeptidase Activities as Early and Predictive Biomarkers of Renal Dysfunction in Cisplatin-Treated Rats

机译:尿氨基肽酶活性作为顺铂治疗大鼠肾功能异常的早期和预测性生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study analyzes the fluorimetric determination of alanyl- (Ala), glutamyl- (Glu), leucyl-cystinyl- (Cys) and aspartyl-aminopeptidase (AspAp) urinary enzymatic activities as early and predictive biomarkers of renal dysfunction in cisplatin-treated rats. Male Wistar rats (n = 8 each group) received a single subcutaneous injection of either saline or cisplatin 3.5 or 7 mg/kg, and urine samples were taken at 0, 1, 2, 3 and 14 days after treatment. In urine samples we determined Ala, Glu, Cys and AspAp activities, proteinuria, N-acetyl-β-D-glucosaminidase (NAG), albumin, and neutrophil gelatinase-associated lipocalin (NGAL). Plasma creatinine, creatinine clearance and renal morphological variables were measured at the end of the experiment. CysAp, NAG and albumin were increased 48 hours after treatment in the cisplatin 3.5 mg/kg treated group. At 24 hours, all urinary aminopeptidase activities and albuminuria were significantly increased in the cisplatin 7 mg/kg treated group. Aminopeptidase urinary activities correlated (p<0.011; r2>0.259) with plasma creatinine, creatinine clearance and/or kidney weight/body weight ratio at the end of the experiment and they could be considered as predictive biomarkers of renal injury severity. ROC-AUC analysis was made to study their sensitivity and specificity to distinguish between treated and untreated rats at day 1. All aminopeptidase activities showed an AUC>0.633. We conclude that Ala, Cys, Glu and AspAp enzymatic activities are early and predictive urinary biomarkers of the renal dysfunction induced by cisplatin. These determinations can be very useful in the prognostic and diagnostic of renal dysfunction in preclinical research and clinical practice.
机译:这项研究分析了荧光测定的丙氨酰-(Ala),谷氨酰-(Glu),亮氨酰-半胱氨酰-(Cys)和天冬氨酰氨肽酶(AspAp)尿液酶活性,作为顺铂治疗的大鼠肾功能障碍的早期和预测性生物标志物。雄性Wistar大鼠(每组n = 8)每只皮下注射盐水或顺铂3.5或7mg / kg,在治疗后0、1、2、3和14天采集尿液样品。在尿液样本中,我们测定了Ala,Glu,Cys和AspAp活性,蛋白尿,N-乙酰基-β-D-氨基葡萄糖苷酶(NAG),白蛋白和中性粒细胞明胶酶相关的脂蛋白(NGAL)。在实验结束时测量血浆肌酐,肌酐清除率和肾脏形态学变量。治疗后48小时,顺铂3.5 mg / kg治疗组的CysAp,NAG和白蛋白升高。在24小时时,顺铂7 mg / kg治疗组的所有尿液氨肽酶活性和白蛋白尿均显着增加。在实验结束时,氨肽酶的尿活动与血浆肌酐,肌酐清除率和/或肾脏重量/体重比相关(p <0.011; r 2 > 0.259),可以将其视为预测性生物标志物肾损伤的严重程度。进行ROC-AUC分析以研究它们的敏感性和特异性,以区分在第1天处理的和未处理的大鼠。所有氨基肽酶活性均显示AUC> 0.633。我们得出的结论是,Ala,Cys,Glu和AspAp的酶促活性是顺铂诱导的肾功能不全的早期和预测性尿液生物标志物。这些测定对于临床前研究和临床实践中肾功能不全的预后和诊断非常有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号